
    
      This study will evaluate the efficacy, safety and pharmacokinetics of Capecitabine (2000
      mg/m2/day po, day 1 pm-day 15 am q3w), Oxaliplatin (130 mg/m2 iv, day 1 q3w) and Bevacizumab
      (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.
    
  